Rabenda V, Manette C, Lemmens R, et al. - The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects. Osteoporos Int, 2006, 17, 1346-1352.
Boonen S, Body JJ, Boutsen Y, et al. - Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteopros Int, 2005, 16, 139-254.
Close P, Neuprez A, Reginster JY. - Development in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother, 2006, 7, 1603-1615.
Delmas PD, Recker RR, Chesnut CH 3rd, et al. - Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int, 2004, 15, 792-798.
Bonnick S, Saag KG, Kiel DP, et al. - Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab, 2006, 91, 2631-2637.
Silverman SL, Watts NB, Delmas PD, et al. - Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy : the risedronate and alendronate (REAL) cohort study. Osteoporos Int, 2007, 18, 25-34.
Reginster JY, Adami S, Lakatos P, et al. - Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis, 2006, 65, 654-661.
Cooper A, Drake J, Brankin E : the PERSIST Investigators. - Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract, 2006, 60, 896-905.
Delmas PD, Adami D, Strugala C, et al. - Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum, 2006, 54, 1838-1846.
Black DM, Schwartz AV, Ensrud KE, et al. - Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA, 2006, 296, 2927-2938.
Greenspan SL, Bone HG, Ettinger MP, et al. - Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med, 2007, 146, 326-339.
Rabenda V, Hanssens L, De Ceulaere F, Reginster JY. - Is there any interest in combining treatments in osteoporosis? Curr Rheum Reviews, 2005, 1, 49-55.
Heaney RP, Recker RR. - Combination and sequential therapy for osteoporosis. N Engl J Med, 2005, 353, 624-625.
Seeman E, Vellas B, Benhamou C, et al. - Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res, 2006, 21, 1113-1120.
O'Donnel S, Cranney A, Wells GA, et al. - Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev, 2006, 18, CD005326.
Reginster JY, Malaise O, Neuprez A, Bruyère O. - Strontium ranelate in the prevention of osteoporotic fractures. Int J Clin Pract, 2007, 61, 324-328.
Boonen S, Lips P, Bouillon R, et al. - Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative meta-analysis of randomized controlled trials. J Clin Endocrinol Metab, 2007, 10, 25-33.
